oncology - HUB Organoids

March 10, 2026

Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Clin Cancer Res | 2025 Dec

March 9, 2026

Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond

npj Biomed. Innov. | 2026 Feb

June 20, 2024

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

J Exp Clin Cancer Res | 2024 Feb

October 11, 2023

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer

Cell Rep | April 2023

February 16, 2022

Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients

Cell | May 2015

February 16, 2022

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

eLife | Nov 2016

February 16, 2022

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity

Cell | Jan 2018

February 16, 2022

Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids

Nat Protoc | April 2021

February 16, 2022

Sequential cancer mutations in cultured human intestinal stem cells

Nature | May 2015

February 16, 2022

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Nat Cancer | April 2022

HUB Organoids

Resources

Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer

Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity

Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids

Sequential cancer mutations in cultured human intestinal stem cells

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Have any questions?